By Sabela Ojea
Shares of United Therapeutics fell on pace for the largest percent decrease in three years after the company's fourth-quarter earnings fell short of expectations.
The stock was down 10%, to $321.90, in Wednesday trading. Shares are down 8.8% year to date, and have fallen 42% over the past 12 months.
The biotechnology company posted a net profit of $301.3 million, or $6.19 a share, compared with $217.1 million, or $4.36 a share, for the same period a year earlier. Analysts surveyed by FactSet had expected earnings of $6.40 a share.
Revenue rose 20%, to $735.9 million, offset by a 2.1% decline in Adcirca sales. Wall Street had expected revenue of $734.7 million, according to FactSet.
Adcirca is used to treat pulmonary arterial hypertension.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
February 26, 2025 12:08 ET (17:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.